Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Zhu S, Liu Y, Wang PC, Gu X, Shan L.

Biomed Res Int. 2017;2017:7929286. doi: 10.1155/2017/7929286. Epub 2017 Jun 29. Review.

2.

Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel.

Wang B, Lv L, Wang Z, Jiang Y, Lv W, Liu X, Wang Z, Zhao Y, Xin H, Xu Q.

Sci Rep. 2015 Nov 16;5:16589. doi: 10.1038/srep16589.

3.

Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study.

Chen PY, Hsieh HY, Huang CY, Lin CY, Wei KC, Liu HL.

J Transl Med. 2015;13:93. doi: 10.1186/s12967-015-0451-y. Epub 2015 Mar 17.

4.

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Kumar P, Patel D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH, Cottle-Delisle C, Merkel R, Yang L, Miettinen M, Puri RK, Kebebew E.

Cancer Med. 2015 Jul;4(7):1060-8. doi: 10.1002/cam4.449. Epub 2015 Mar 13.

5.

Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Azad TD, Pan J, Connolly ID, Remington A, Wilson CM, Grant GA.

Neurosurg Focus. 2015 Mar;38(3):E9. doi: 10.3171/2014.12.FOCUS14758. Review.

6.

Synergistic interaction between selective drugs in cell populations models.

Doldán-Martelli V, Míguez DG.

PLoS One. 2015 Feb 11;10(2):e0117558. doi: 10.1371/journal.pone.0117558. eCollection 2015.

7.

Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.

Geskin LJ, Viragova S, Stolz DB, Fuschiotti P.

Blood. 2015 Apr 30;125(18):2798-805. doi: 10.1182/blood-2014-07-590398. Epub 2015 Jan 27.

8.

Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain.

Sarkar G, Curran GL, Sarkaria JN, Lowe VJ, Jenkins RB.

PLoS One. 2014 May 21;9(5):e97655. doi: 10.1371/journal.pone.0097655. eCollection 2014.

9.

A mathematical model for the rational design of chimeric ligands in selective drug therapies.

Doldán-Martelli V, Guantes R, Míguez DG.

CPT Pharmacometrics Syst Pharmacol. 2013 Feb 13;2:e26. doi: 10.1038/psp.2013.2.

10.

Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.

Li LQ, Shen F, Xu XY, Zhang H, Yang XF, Liu WG.

ScientificWorldJournal. 2013;2013:951343. doi: 10.1155/2013/951343. Epub 2013 Mar 3.

11.

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A.

Neuro Oncol. 2012 Oct;14(10):1239-53. Epub 2012 Sep 5.

12.

IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications.

Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A.

Transl Oncol. 2011 Dec;4(6):390-400. Epub 2011 Dec 1.

13.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.

Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA.

J Neurooncol. 2011 Jun;103(2):255-66. doi: 10.1007/s11060-010-0392-5. Epub 2010 Sep 10.

14.

Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.

Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahloun AG, Morris JC, Puri RK, Pacak K.

J Clin Endocrinol Metab. 2009 Aug;94(8):2952-7. doi: 10.1210/jc.2009-0309. Epub 2009 Jun 2.

15.

Targeted therapies for malignant glioma: progress and potential.

Mercer RW, Tyler MA, Ulasov IV, Lesniak MS.

BioDrugs. 2009;23(1):25-35. doi: 10.2165/00063030-200923010-00003. Review.

16.

Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.

Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE.

Clin Cancer Res. 2008 Jun 15;14(12):3832-9. doi: 10.1158/1078-0432.CCR-07-5067.

17.
18.

Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK; US Pediatric Brain Tumor Consortium.

Neuro Oncol. 2008 Jun;10(3):265-74. doi: 10.1215/15228517-2007-066. Epub 2008 Apr 22.

19.

Image-guided convection-enhanced delivery platform in the treatment of neurological diseases.

Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS.

Neurotherapeutics. 2008 Jan;5(1):123-7. doi: 10.1016/j.nurt.2007.10.064. Review.

20.

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS.

Neuro Oncol. 2007 Oct;9(4):393-403. Epub 2007 Jul 24.

Supplemental Content

Support Center